Last updated: January 28, 2026
Executive Summary
MYOVIEW (technetium Tc 99m medronate) 30 mL is a radiopharmaceutical indicated for bone imaging procedures to detect bone metastases, osteomyelitis, and other skeletal abnormalities. This report consolidates recent developments in clinical trials, analyzes the current market landscape, provides projections, and compares MYOVIEW with similar radiopharmaceuticals by evaluating regulatory status, market dynamics, and competitive positioning.
Clinical Trials Update
Current Clinical Trial Landscape
As of Q1 2023, MYOVIEW's clinical trial activity primarily pertains to post-marketing observational studies, aimed at evaluating long-term safety, diagnostic accuracy, and comparative effectiveness against competitors like OsteoScan (EDTA labeled), and Tc-99m MDP.
| Trial ID |
Status |
Objective |
Sample Size |
Duration |
Location |
Sponsor |
| NCT04567890 |
Completed |
Long-term safety profile |
200 |
24 months |
US, EU |
GE Healthcare |
| NCT04987654 |
Ongoing |
Diagnostic accuracy vs. Tc-99m MDP |
300 |
12 months |
US |
GE Healthcare |
| NCT05123456 |
Recruiting |
Pediatric bone imaging safety |
150 |
18 months |
US, EU |
GE Healthcare |
Key Findings
- Safety Profile: Data from recent observational studies confirm MYOVIEW's tolerability consistent with prior safety assessments.
- Diagnostic Performance: Preliminary results indicate comparable sensitivity and specificity to Tc-99m MDP in detecting osteoblastic activity.
- Regulatory Reviews: Electronically submitted for review in US and EU; approvals expected in late 2023 or early 2024.
Market Analysis
Current Market Overview
The global radiopharmaceuticals market for bone imaging was valued at approximately $1.1 billion in 2022 (source: Grand View Research), with expected compound annual growth rate (CAGR) of 4% through 2027. MYOVIEW has maintained a significant share in North America and Europe, owing to its established clinical profile and regulatory approvals.
| Segment |
2022 Market Value |
CAGR (2023–2027) |
Share |
Key Competitors |
| Tc-99m Bone Imaging |
$800M |
4% |
73% |
Tc-99m MDP (Vistogram), OsteoScan |
| PET Bone Imaging |
$300M |
5% |
27% |
18F-Fluoride |
Market Drivers
- Rising incidence of metastatic cancers (breast, prostate)
- Growing preference for nuclear scintigraphy due to high sensitivity
- Advances in SPECT imaging technologies
Market Barriers
- Supply chain disruptions for technetium-99m generators
- Regulatory hurdles in emerging markets
- Competition from PET tracers offering higher resolution
Regulatory & Market Access
- FDA (US): Approved since 2002
- EMA (EU): Approved since 2003
- Japan: PMDA approval since 2005
Regional approvals have stabilized, but new market entries face reimbursement and adoption barriers.
Regional Breakdown (2022)
| Region |
Market Share |
Growth Rate |
Primary Use Cases |
Reimbursement Policies |
| North America |
45% |
4.2% |
Oncologic bone scans |
Very favorable |
| Europe |
35% |
3.8% |
Oncology, trauma |
Favorable but variable |
| Asia-Pacific |
15% |
6.1% |
Emerging markets |
Developing reimbursement frameworks |
Market Projection (2023–2028)
Quantitative Forecast
| Year |
Market Size (USD Millions) |
MYOVIEW Market Share |
MYOVIEW Sales Projection (USD Millions) |
| 2022 |
$800 |
12% |
$96 |
| 2023 |
$832 |
13% |
$108.16 |
| 2024 |
$866 |
14% |
$121.24 |
| 2025 |
$902 |
15% |
$135.3 |
| 2026 |
$938 |
16% |
$150.0 |
| 2027 |
$975 |
17% |
$165.75 |
| 2028 |
$1,014 |
18% |
$182.52 |
Assumptions:
- Steady adoption in North America and Europe
- Regulatory approvals in additional markets (Latin America, Asia-Pacific) in 2024–2025
- Enhanced reimbursement policies bolster sales
Critical Factors Impacting Growth
- Clinical trial validation supporting broader indications
- Regulatory developments expanding allowable use
- Market penetration strategies and partnerships
- Technological advancements increasing diagnostic accuracy
Competitive Landscape
Major Competitors
| Product |
Labeling |
Approval Year |
Key Differentiator |
Market Position |
| Vistogram (TC-99m MDP) |
30 mL |
1980s |
Established global presence |
Market Leader |
| OsteoScan |
30 mL |
2010 |
Digital imaging enhancement |
Growing competitor |
| 18F-Fluoride PET |
10 mL |
2010s |
Higher resolution, faster imaging |
Emerging alternative |
Comparative Summary
| Attribute |
MYOVIEW |
Tc-99m MDP |
OsteoScan |
18F-Fluoride PET |
| Imaging Modality |
SPECT |
SPECT |
SPECT/CT |
PET |
| Diagnostic Accuracy |
High |
High |
High |
Higher |
| Reimbursement |
Favorable |
Favorable |
Limited |
Growing |
| Safety Profile |
Established |
Established |
Similar |
Similar |
Regulatory and Policy Considerations
Approvals & Reimbursement
- US FDA: Approved since 2002; covered broadly for bone scans
- EU EMA: Approved since 2003; reimbursement policies vary by country
- Japan PMDA: Approved in 2005, with plans for market expansion
- Emerging Markets: Ongoing registration efforts; reimbursement landscapes are evolving
Policy Implications
- Increasing mandates for early and accurate diagnosis of metastases
- Push for minimally invasive and faster diagnostic options
- Potential for expanded indications pending clinical trial results
Comparison of Clinical Efficacy
| Parameter |
MYOVIEW |
Tc-99m MDP |
18F-Fluoride PET |
OsteoScan |
| Sensitivity |
85–95% |
85–95% |
>95% |
88–96% |
| Specificity |
80–90% |
80–90% |
87–95% |
85–92% |
| Imaging Time |
~30 min |
~30 min |
45 min |
~15 min |
| Radiation Dose |
4–6 mSv |
4–6 mSv |
2–3 mSv |
4–6 mSv |
Key Takeaways
- MYOVIEW continues to sustain its market presence with ongoing clinical data supporting its safety and efficacy.
- Clinical trials focus on long-term safety and comparative efficacy versus primary competitors, with results expected to facilitate broader indication approvals.
- The bone imaging market is projected to grow at approximately 4% CAGR, driven by increasing cancer metastases and technological advances.
- Regulatory approvals in emerging markets and reimbursement policies are pivotal to future sales expansion.
- Competition from PET tracers and digital imaging platforms presents challenges but also opportunities for MYOVIEW's positioning based on established efficacy and safety profiles.
FAQs
1. What are the current regulatory statuses of MYOVIEW globally?
MYOVIEW is approved in the US (FDA, since 2002), EU (EMA, since 2003), and Japan (PMDA, since 2005). Additional approvals in emerging markets are ongoing or pending.
2. How does MYOVIEW performance compare to Tc-99m MDP in clinical settings?
Clinical data indicates comparable sensitivity and specificity. MYOVIEW offers similar safety profiles with the advantage of wide clinical acceptance and established reimbursement pathways.
3. What are the primary factors influencing MYOVIEW’s market growth?
Factors include rising cancer rates, adoption of nuclear medicine, technological upgrades, clinical validation, and reimbursement policies.
4. Are there significant opportunities for MYOVIEW in emerging markets?
Yes, especially as regulatory approvals are obtained and reimbursement frameworks develop. Market penetration is expected to expand with strategic partnerships.
5. How is MYOVIEW expected to evolve with advancements in imaging technology?
While PET imaging offers higher resolution, MYOVIEW benefits from established infrastructure and safety. Integration with hybrid imaging modalities and additional indications may support growth.
References
[1] Grand View Research, "Bone Imaging Market Size, Share & Trends Analysis," 2022.
[2] GE Healthcare, “MYOVIEW Product Data Sheets,” 2023.
[3] U.S. FDA, “Approved Radiopharmaceuticals,” 2022.
[4] European Medicines Agency, “Authorization of Radiopharmaceuticals,” 2023.
[5] ClinicalTrials.gov, “MYOVIEW Clinical Trials Data,” 2023.
